Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss per share

Loss per share

9 Months Ended

Sep. 30, 2018

Loss per share

Loss per share

Note 5 — Loss per share

The numerator for the basic and diluted income (loss) per share is as follows (in thousands):

	Three months ended					Nine months ended
	September 30,					September 30,
	2018		2017			2018			2017
Net income (loss) attributable to ordinary shareholders	$	5,242	$	(878	)	$	(59,341	)	$	(42,875	)
Numerator for basic income (loss) per share	5,242		(878		)	(59,341		)	(42,875		)
Numerator for dilued income (loss) per share	5,242		(878		)	(59,341		)	(42,875		)

The denominator for the basic and diluted income (loss) per share is as follows:

	Three months ended		Nine months ended
	September 30,		September 30,
	2018	2017	2018	2017
Denominator for basic income (loss) per share - Weighted average shares outstanding	582,004,954	561,239,864	573,796,275	516,352,141
Effect of dilutive securities:
Employee stock options	39,759,247	—	—	—

Denominator for diluted income (loss) per share	621,764,201	561,239,864	573,796,275	516,352,141

The dilutive effect of 2,791,651 and 75,087,783 stock options have been excluded from the diluted earnings (loss) per share calculation for the three months ended September 30, 2018 and 2017, respectively, because they would have an antidilutive effect on the earnings (loss) per share for the period. The dilutive effect of 88,869,497 and 69,136,398 stock options have been excluded from the diluted loss per share calculation for the nine months ended September 30, 2018 and 2017, respectively, because they would have an antidilutive effect on the income (loss) per share for the period.